(Q39455537)

English

Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

author name string

Guohong Han

1

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Jijin Yang

2

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Guoliang Shao

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Gaojun Teng

4

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Maoqiang Wang

5

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Jianyong Yang

6

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Zhaoyu Liu

7

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Gansheng Feng

8

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Renjie Yang

9

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Ligong Lu

10

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Yee Chao

11

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Jianhua Wang

12

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

language of work or name

0 references

publication date

1 March 2013

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Future Oncology

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

403-410

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

Management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

Management of hepatocellular carcinoma: An update

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

Updated treatment approach to hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

Angiogenesis in liver disease

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

Genomics and signaling pathways in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

Angiogenesis and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

Increased Expression of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.11

21 January 2018

Identifiers

10.2217/FON.13.11

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39455537&oldid=1829124949"